METASTATIC COLORECTAL ADENOCARCINOMA
Clinical trials for METASTATIC COLORECTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC COLORECTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC COLORECTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo aims to tackle stubborn colorectal cancer
Disease control Recruiting nowThis trial is testing whether combining pidnarulex (a drug that blocks cancer cell growth) with cemiplimab (an immunotherapy that helps the immune system attack cancer) is safe and effective for people with advanced colorectal cancer that no longer responds to standard treatments…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a vitamin b derivative boost chemo for advanced colon cancer?
Disease control Recruiting nowThis study tests a new drug called arfolitixorin for people with metastatic colorectal cancer (cancer that has spread). The drug is a form of vitamin B that may make standard chemotherapy work better. About 90 participants will receive arfolitixorin along with usual chemo drugs, …
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Isofol Medical AB • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for advanced bowel cancer: experimental drug combo enters major trial
Disease control Recruiting nowThis study tests whether a new drug called pumitamig, combined with chemotherapy, works better than the current standard treatment (bevacizumab plus chemo) for people with advanced colorectal cancer that cannot be removed by surgery. About 990 adults who have not yet been treated…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Smart dosing: tailoring cancer drug levels could extend life for colorectal patients
Disease control Recruiting nowThis Phase 3 trial tests whether adjusting the dose of bevacizumab based on each patient's drug levels can better control metastatic colorectal cancer. About 244 people will receive either standard or personalized dosing alongside chemotherapy. The main goal is to see if personal…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: University Hospital, Tours • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for colorectal cancer: experimental drug faces off against avastin
Disease control Recruiting nowThis Phase 3 trial is testing whether a new medicine called PF-08634404, combined with standard chemotherapy, works better than the current treatment Avastin plus chemo for people whose colorectal cancer has spread. About 800 participants who have not had prior treatment for meta…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New trial zaps spreading colon cancer with precision: could it be a Game-Changer?
Disease control Recruiting nowThis phase III trial is testing whether adding focused treatments—like high-dose radiation, surgery, or heat ablation—to standard chemotherapy can help people with colorectal cancer that has spread to up to four sites. The goal is to see if destroying those metastatic tumors impr…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug cocktail targets metastatic colorectal cancer in early trial
Disease control Recruiting nowThis early-phase trial is testing whether adding an experimental drug called CA-4948 to standard chemotherapy (FOLFOX) and a targeted therapy (bevacizumab) is safe for people with metastatic colorectal cancer. About 24 adults whose cancer has spread and cannot be surgically remov…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat colorectal cancer
Disease control Recruiting nowThis early-stage trial tests a new type of immune cell therapy (CAR-NK cells) in people with advanced colorectal cancer that has not responded to standard treatments. The cells are designed to target two cancer-related proteins at once, based on each patient's tumor markers. The …
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New immunotherapy cocktails aim to fight colorectal cancer in the liver
Disease control Recruiting nowThis study tests different combinations of immunotherapy drugs (with or without radiation) in 24 people with colorectal cancer that has spread to the liver and who are scheduled for surgery. The goal is to see if these treatments change the immune environment inside the liver tum…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for colorectal cancer: experimental combo trial launches
Disease control Recruiting nowThis phase 2 trial is testing a new immunotherapy drug called volrustomig, combined with standard chemotherapy (FOLFIRI) and bevacizumab, in 120 people with metastatic colorectal cancer. The goal is to see if the combination is safe and helps control the cancer longer. Participan…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New pill shows promise in early trial for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new oral drug, PF-08032562, in people with advanced breast or colorectal cancer that has spread. The drug is given alone or with other cancer treatments. The main goals are to check safety, find the right dose, and see if it shrinks tumors. Abo…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New Antibody-Drug cocktail targets tough colorectal cancer
Disease control Recruiting nowThis study tests a new drug called JS212, which is designed to target two proteins on cancer cells (EGFR and HER3) and deliver a chemotherapy-like payload directly to them. It is being tested in combination with other standard cancer drugs in 80 adults with metastatic colorectal …
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a combination of two drugs—trifluridine/tipiracil (a chemotherapy) and talazoparib (a targeted therapy)—in people with advanced colorectal or gastroesophageal cancers that have spread. The main goals are to find the safest dose and understand side eff…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug cocktails aim to shrink Hard-to-Treat gut cancers
Disease control Recruiting nowThis study is testing several new experimental drugs (RAS(ON) inhibitors) combined with standard chemotherapy or other targeted therapies in people with advanced colorectal or pancreatic cancer that has spread. The goal is to see if these combinations are safe and can shrink tumo…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug combo aims to fight Hard-to-Treat colorectal cancer
Disease control Recruiting nowThis phase 2 trial tests whether combining two drugs—fruquintinib and TAS-102—works better than fruquintinib alone for people with advanced colorectal cancer that hasn't responded to prior treatments. About 120 adults will be randomly assigned to one of the two groups. The main g…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Criterium, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Triple-Drug attack offers hope for Hard-to-Treat colorectal cancer
Disease control Recruiting nowThis study tests whether a combination of three drugs (tucidinostat, sintilimab, and bevacizumab) can help people with a specific type of advanced colorectal cancer (MSS/pMMR) who have already tried at least two standard treatments. About 430 adults aged 18 to 75 will be randomly…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Could a Fasting-Mimicking diet boost immunotherapy and vitamin c against tough colorectal cancer?
Disease control Recruiting nowThis early-phase trial is testing whether combining two immunotherapy drugs (botensilimab and balstilimab) with a low-sugar, calorie-restricted diet and high-dose vitamin C is safe and tolerable for people with a specific type of advanced colorectal cancer (KRAS-mutant). The stud…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug targets Hard-to-Treat colorectal cancer in early trial
Disease control Recruiting nowThis study tests a new drug, tegavivint, in people with metastatic colorectal cancer that has worsened after at least two prior treatments. The trial aims to find a safe dose and see if the drug shrinks tumors when used alone or with standard therapies. About 126 adults with spec…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: HonorHealth Research Institute • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New CAR-NK cell therapy takes on colorectal cancer
Disease control Recruiting nowThis study tests a new treatment made from donated cord blood cells that are engineered to recognize and attack colorectal cancer cells. It is for people with advanced or metastatic colorectal cancer that has not responded to standard treatments. The trial will check safety and e…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New Chemo-Free combo shows promise for colorectal cancer
Disease control Recruiting nowThis Phase II trial tests a combination of two drugs, anlotinib and sintilimab, as a first treatment for advanced colorectal cancer that has spread but not to the liver. The goal is to shrink tumors and control the disease without using standard chemotherapy. About 37 patients wh…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New chemo cocktail aims to outperform standard care in colorectal cancer
Disease control Recruiting nowThis Phase 3 trial tests whether a new combination of chemotherapy drugs (NALIRIFOX) plus targeted therapy works better than the standard FOLFOX regimen for people with metastatic colorectal cancer that has not been treated before. About 144 participants will receive one of the t…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New liposomal combo aims to control advanced colorectal cancer
Disease control Recruiting nowThis study tests a new form of chemotherapy (liposomal irinotecan) combined with standard drugs for people with advanced colorectal cancer that has not responded to first treatment. About 100 adults aged 18-75 will receive this combination to see if it shrinks tumors and delays c…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New Three-Drug cocktail takes on tough colorectal cancer
Disease control Recruiting nowThis phase 2 trial tests whether adding an immunotherapy drug (envafolimab) and a stronger chemotherapy mix (mFOLFOXIRI) to the standard treatment (cetuximab plus mFOLFOX6) can better control advanced left-sided colorectal cancer that has spread. About 198 people with a specific …
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New hope for cancer patients with dangerous gene flaw: safer chemo combo tested
Disease control Recruiting nowThis study tests a different chemotherapy drug (trifluridine/tipiracil) for people with metastatic colorectal or gastroesophageal cancer who have a genetic condition (DPD deficiency) that makes standard chemo very toxic. About 73 participants will receive this drug along with oth…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope: Chemo-Free cocktail targets advanced colorectal cancer
Disease control Recruiting nowThis study tests whether a combination of targeted drugs (cetuximab beta and fruquintinib) with or without immunotherapy can control advanced colorectal cancer without traditional chemotherapy. About 70 people with a specific genetic type (RAS/BRAF wild-type) will receive these d…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New immunotherapy cocktail targets tough colon cancer
Disease control Recruiting nowThis phase 2 trial is testing whether adding an immunotherapy drug (AK104) to standard chemotherapy and a targeted therapy (cetuximab or bevacizumab) can shrink tumors in people with a specific type of advanced colorectal cancer (MSS type) that has already been treated once. The …
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Radio waves plus targeted drug aim to extend life in tough-to-treat colon cancer
Disease control Recruiting nowThis study tests whether adding a non-invasive device that delivers low-level radio waves (AM RF EMF) to the targeted drug fruquintinib can help people with metastatic colorectal cancer that has stopped responding to other treatments live longer. About 102 participants will recei…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New blood test could predict which colorectal cancer patients benefit from targeted drugs
Diagnosis Recruiting nowThis study aims to develop a blood test that uses epigenetic markers (chemical changes on DNA) to predict whether a patient with metastatic colorectal cancer will respond to targeted therapies like cetuximab or bevacizumab. Researchers will analyze blood samples from 500 patients…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 07:56 UTC
-
Blood test may predict chemo success in advanced colon cancer
Knowledge-focused Recruiting nowThis study is looking for a way to predict which patients with advanced colorectal cancer will benefit from standard chemotherapy. Researchers will analyze blood samples from 600 patients to find specific markers that separate responders from non-responders. The goal is to help d…
Matched conditions: METASTATIC COLORECTAL ADENOCARCINOMA
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC